GlobeNewswire

Clariant’s shareholders approve all agenda items

Share
  • Distribution of CHF 0.70 for Group’s performance over past two financial years approved
  • Integrated Report and Group Consolidated Financial Statements for fiscal year 2020 approved
  • Shareholders approve Compensation Report 2020 on an advisory basis
  • Günter von Au newly elected as Chairman of the Board of Directors

Muttenz,   April 7, 2021– At today’s Annual General Meeting, the shareholders of Clariant Ltd, a focused, sustainable and innovative specialty chemical company, approved all agenda items and resolutions proposed by the Board of Directors, including the election of Günter von Au as new Chairman of the Board of Directors.

Due to the ongoing situation with regard to the spread of the coronavirus, shareholders could not attend this year’s Annual General Meeting in person and could exercise their rights exclusively via the independent proxy. Overall, 231 091 133 shares or around 69.62 % of the share capital of Clariant were represented.

Günter von Au, Chairman of Clariant’s Board of Directors, said “It is a great honor for me to be elected as Chairman of the Board of Directors, especially because of the close relationship that I have with this company for almost a decade now. Together with all my fellow board members as well as CEO Conrad Keijzer, I look forward to continuing Clariant’s successful path towards becoming one of the world’s leading companies for specialty chemicals and create value for all stakeholders, including shareholders.”

“I wish to thank all Clariant customers, employees and shareholders for the trust, commitment and loyalty that I have experienced during my time as Member of the Board, CEO and Chairman. I am proud of all our achievements and am convinced that I leave Clariant on a strong basis from which it can continue its path of sustainable, profitable growth”, commented Hariolf Kottmann, former Chairman of Clariant’s Board of Directors.

Conrad Keijzer, CEO of Clariant, said: “The 2020 results proof the resilience of our portfolio and the hard work of our teams. We will now focus on unleashing the full potential of our three core Business Areas to strengthen our profile as a true specialty chemicals company. Today, I have shared my confidence with our shareholders that our strong market positions can deliver leading financial performance and thereby further increase the value of Clariant.”

At the Annual General Meeting, the Integrated Report as well as the Financial Statements and Consolidated Financial Statements of Clariant for the 2020 fiscal year were approved with 99.89 % of the votes. The 2020 Compensation Report was also approved on an advisory basis with 92.55 % of the votes. The members of the Board of Directors and the Executive Committee were discharged with 99.47 % of the votes.

In addition, the Annual General Meeting approved a distribution through capital reduction (par value reduction) of CHF 0.70 per share, with 99.84 % of the votes. The CHF 0.70 distribution should not be interpreted as a recurring dividend or distribution as it takes into consideration the Group’s performance of the past two financial years (CHF 0.55 per share for FY 2019 and CHF 0.15 per share for FY 2020).

The Annual General Meeting approved the election of Günter von Au as new Chairman of the Board of Directors until the Annual General Meeting 2022 with 97.96 %. Günter von Au has been a member of the Board of Directors since 2012 and acted as Vice Chairman from 2012 to 2018. The ten other members of the Board of Directors were also reelected by a large majority until the next Annual General Meeting. Further, Dr. Balthasar Settelen, attorney, was reelected as independent proxy until the next Annual General Meeting and PricewaterhouseCoopers AG was confirmed as the statutory auditor for 2021.

The proposal for total compensation of the Board of Directors for the term from the 2021 to the 2022 Annual General Meeting was approved with 92.82 % of the votes, as was the total compensation of the Executive Committee for the 2022 fiscal year, with 93.39 % of the votes.


Corporate Media RelationsInvestor Relations
Jochen Dubiel

Phone +41 61 469 63 63
jochen.dubiel@clariant.com
andreas schwarzwälder

Phone +41 61 469 63 73
andreas.schwarzwaelder@clariant.com
Claudia Kamensky

Phone +41 61 469 63 63
claudia.kamensky@clariant.com
Maria Ivek

Phone +41 61 469 63 73
maria.ivek@clariant.com
Thijs Bouwens

Phone +41 61 469 63 63
thijs.bouwens@clariant.com
Alexander Kamb

Phone +41 61 469 63 73
alexander.kamb@clariant.com
Follow us on Twitter, Facebook, LinkedIn, Instagram.


This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.
www.clariant.com


Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2020, the company employed a total workforce of 13 235. In the financial year 2020, Clariant recorded sales of CHF 3.860 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

Attachments


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Notification according to chapter 9, section 10 of the Securities Market Act: Bolero Holdings SARL ownership in Suominen decreases to below 5 percent16.4.2021 15:30:00 CEST | Press release

Suominen Corporation, stock exchange release on April 16, 2021 at 4.30 p.m. (EET). Suominen Corporation has on April 16, 2021 received a notification referred to in Chapter 9, Section 5 and 6 of the Securities Market Act. According to the notification, the shareholding of Bolero Holdings SARL in Suominen Corporation has fallen below the 5% flagging threshold. Total positions of person subject to the notification obligation: % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of the issuerResulting situation on the date on which threshold was crossed or reachedBelow 5%n/aBelow 5%58,259,219Position of previous notification (if applicable)5.81%n/a5.81% Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rightsClass/type of sharesNumber of shares and voting rights% of shares and votin

Correction: REGARDING DRAFT ALTERNATIVE RESOLUTION SUBMITTED TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS16.4.2021 14:49:32 CEST | Press release

Correction: the number of shares indicated – 380.396.585 and declared dividends per share – 0,0198 EUR. On 15 April 2021 AB “Klaipėdos nafta” (hereinafter – Company) received a proposal from the Ministry of Energy of the Republic of Lithuania (hereinafter referred to as the Shareholder), that executes the rights of the Shareholder – the Republic of Lithuania that owns 275 687 444 ordinary registered shares, making 72,45 per cent of the total amount of the Company’s shares, on an alternative draft resolution of the issue on the agenda of the ordinary registered meeting of shareholders of the Company to be convened on 30 April 2021. Following paragraphs 3, 4 and 5 of Article 25 of the Law on Companies of the Republic of Lithuania, the Shareholder as the person exercising the right to propose draft resolutions of the Company’s General Meeting, holding shares that grant at least 1/20 of all the votes, proposes to approve the following draft resolution of the fourth item on the agenda of th

Sampo plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)16.4.2021 14:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 16 April 2021 at 3:30 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of voting rights attached to Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 April 2021 above five (5) per cent of Sampo plc’s total voting rights. In addition, the disclosure obligation arose due to the number of Sampo A shares owned directly or indirectly by BlackRock, Inc. and its funds increasing above 5 per cent. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions

CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 1016.4.2021 12:45:00 CEST | Press release

Allentown, April 16, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners to Announce First Quarter 2021 Earnings Results on May 10 ALLENTOWN, PA, April 16, 2021 – CrossAmerica Partners LP (NYSE: CAPL) today announced that it will release its first quarter 2021 results after the market closes on Monday, May 10, 2021. In conjunction with the news release, management will host a conference call on Tuesday, May 11, at 9:00 a.m. Eastern Time. The conference call numbers are 800-774-6070 or 630-691-2753 and the passcode for both is 7265208#. A live audio webcast of the conference call and the related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on that same day on the investor section of the CrossAmerica website (www.crossamericapartners.com). To listen to the audio webcast, go to https://caplp.gcs-web.com/webcasts-presentations https://caplp.gcs-web.com/webcasts-presentations. A

Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD16.4.2021 11:00:00 CEST | Press release

Press release, Helsinki, 16.04.2021, 12.00 pm (EEST) Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression. Oladele Adebogun M.D. said, “I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the number of pat

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS16.4.2021 10:08:23 CEST | Press release

Auction date2021-04-16Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 400Volume offered, SEK mln4,000Volume bought, SEK mln750Number of bids12Number of accepted bids3Average yield0.367 %Lowest accepted yield0.367 %Highest yield0.368 %% accepted at lowest yield 65.00 Auction date2021-04-16Loan1053Coupon3.50 %ISIN-codeSE0002829192Maturity2039-03-30Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,400Volume bought, SEK mln500Number of bids5Number of accepted bids2Average yield0.696 %Lowest accepted yield0.693 %Highest yield0.698 %% accepted at lowest yield 100.00 Auction date2021-04-16LoanREGS Kingdom of SwedenCoupon0.125 %ISIN-codeXS2226974504Maturity2030-09-09Tendered volume, SEK mln250 +/- 250Volume offered, SEK mln600Volume bought, SEK mln250Number of bids6Number of accepted bids3Average yield0.287 %Lowest accepted yield0.281 %Highest yield0.291 %% accepted at lowest yield 50.00

Prostate cancer study to be initiated at Uppsala University Hospital with NanoZolid technology®16.4.2021 09:00:00 CEST | Press release

UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an application for a new clinical study at Uppsala University Hospital has been submitted. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in men with prostate cancer who are scheduled for prostatectomy. The trial is originated by the principal investigator of the trial, Dr Michael Häggman, Associate Professor at the Department of Surgical Sciences in Urology, Uppsala University Hospital. The study is planned to start in mid of this year and it will enroll 10- 15 patients to be treated with NZ-DTX prior to planned surgery. “The NanoZolid technology is suitable to combine with the MRI/TRUS injection technique for a high precision intratumoral delivery of NZ-DTX Depot. Treating patients prior to removal of the prostate gland will provide exhaustive information with regards to local effects in the tumor and surrounding tissue”, commented Dr Michael Häggman. “We are very pleased